Stranica 1 iz 32 rezultatima
The authors analyze data of determination of alpha 1 proteinase inhibitor in patients with myocardial infarction depending on the severity of the disease. It is suggested that the quantitative values of alpha 1 proteinase inhibitors of the blood plasma may be used in the diagnosis and prognosis of
Our experiments have shown that in cats in the early phase after experimental myocardial infarction, the volume of extravascular fluid increases in the lungs while the intravascular volume decreases. A hemoconcentration developed with increased hematocrit and a fall in plasma volume. The thrombocyte
The purposes of this study were to investigate the sequential changes of PMN elastase during evolving myocardial infarction, and also to ascertain whether or not ulinastatin (UL), a clinically useful protease inhibitor, would affect the extent of ischemic myocardial injury. The levels of plasma PMN
Serine proteinase inhibitor A3 (Serpina3), initially discovered as an acute phase plasma protease inhibitor, has been demonstrated in the pathology of complex human disorders, but it is yet to be discovered following acute myocardial infarction (AMI) in clinical practice. Therefore, we Plasma concentrations of polymorphonuclear granulocytes elastase (PMN elastase) in complex with alpha-1 proteinase inhibitor are a marker of neutrophil activation. The latter complex, creatine kinase and cardiac troponin T, were measured in peripheral venous blood samples serially drawn in 39
The purpose of this study is to clarify whether cysteine proteinases play an important role in the degradation of myocardial proteins in the infarcted tissue. We studied the effects of a cysteine proteinase inhibitor, Ep459, on degradation of cardiac structural proteins caused by ischemia due to
To test the hypothesis that cellular proteinases contribute to ischemic myocellular death, measurements were made of tyrosine release (an index of overall proteolysis) from incubated slices of nonischemic and ischemic myocardium obtained at various times after coronary artery occlusion in rats.
BACKGROUND
Polymorphisms in candidate genes related to lipid metabolism, thrombosis, hemostasis, cell-matrix adhesion, and inflammation have been suggested clinically useful in risk assessment of cardiovascular disease.
METHODS
We evaluated a panel of 92 candidate gene polymorphisms, using a
beta-Amyloid protein precursors (APP) having proteinase inhibitor domains (APPI) were quantified by a new sandwich enzyme linked immunosorbent assay for detection of active (free) form of proteinase inhibitors by using trypsin in place of the first antibody and by denaturation of APPI-trypsin
According to clinical characteristics and serum levels of alpha 1-proteinase inhibitor in the acute period (1-3 days), four groups of patients with myocardial infarction were identified. The most severe myocardial infarction was observed in patients from Groups 1 and 4. It was found that the serum
OBJECTIVE
to study changes of serum levels of nonspecific proteinases, their inhibitors, and proinflammatory cytokines during short term observation of patients with acute myocardial infarction (MI).
METHODS
We included in this prospective short-term study 82 patients (27 with uncomplicated non-Q
Echocardiography in control narcotized rats (n=12) revealed that acute single-stage ligation of coronary artery induced a rapid and significant decrease in systolic function of the heart, which attained minimum to postischemic minutes 10-20 and then gradually restored during 60 min after coronary
Neuroserpin, a recently identified inhibitor of tissue-type plasminogen activator (tPA), is primarily localized to neurons within the central nervous system, where it is thought to regulate tPA activity. In the present study neuroserpin expression and its potential therapeutic benefits were examined